Advertisement

Digestive Diseases and Sciences

, Volume 59, Issue 8, pp 1743–1753 | Cite as

miR-638 Suppresses Cell Proliferation in Gastric Cancer by Targeting Sp2

  • Ling Yu Zhao
  • Yu Yao
  • Jia Han
  • Juan Yang
  • Xiao Fei Wang
  • Dong Dong Tong
  • Tu Sheng Song
  • Chen HuangEmail author
  • Yuan ShaoEmail author
Original Article

Abstract

Background

MicroRNAs play important roles in the development and progression of various cancers. Recent studies have shown that miR-638 was downregulated in several tumors; however, its role in gastric cancer (GC) has not been investigated in detail.

Aims

The purpose of this study was to determine the role of miR-638 and to elucidate its regulatory mechanism in GC.

Methods

The expression levels of miR-638 and specificity protein 2 (Sp2) were detected by real-time PCR and Western blotting in GC. After pcDNA6.2-GW/EmGFP-miR-638 vector, miR-638 inhibitor and Sp2-siRNA transfection, the AGS cell proliferation was investigated by MTT assay and cell cycle, and apoptosis was detected using the Annexin V/PI. In addition, the regulation of Sp2 by miR-638 was evaluated by real-time RT-PCR, Western blot and luciferase reporter assays; cyclin D1 expression was measured by Western blotting.

Results

The expression of miR-638 is dramatically down-regulated and Sp2 expression is remarkably up-regulated in GC tissues. Luciferase assays revealed that miR-638 inhibited Sp2 expression by targeting the 3′-UTR of Sp2 mRNA. Overexpression of miR-638 and Sp2-siRNA reduced Sp2 expression at both the mRNA and protein levels in vitro, and inhibition of miR-638 increased Sp2 expression. Moreover, we found that miR-638 overexpression and Sp2-siRNA markedly suppressed cell proliferation with decreasing expression of cyclin D1 and inducing G1-phase cell-cycle arrest in vitro; inhibition of miR-638 significantly promoted cell proliferation by increasing expression of cyclin D1 and leading more cells into the S and G2/M phase.

Conclusions

Our results demonstrated that miR-638 suppressed GC cell proliferation by targeting Sp2 with influence on the expression of cyclin D1. We suggest that miR-638 might be a candidate predictor or an anticancer therapeutic target for GC patients.

Keywords

miR-638 Gastric cancer Sp2 Proliferation 

Notes

Acknowledgments

This work was supported by a grant from China Postdoctoral Science Foundation grant (No. 2013M542358) and a fund from the Fundamental Research Funds for the Central Universities, China.

Conflict of interest

None.

References

  1. 1.
    Liu H, Zhu L, Liu B, et al. RGenome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012;316:196–203.PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000, the global picture. Eur J Cancer. 2001;37:S4–S66.PubMedCrossRefGoogle Scholar
  3. 3.
    Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat Rev Cancer. 2003;3:592–600.PubMedCrossRefGoogle Scholar
  4. 4.
    Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269.PubMedCrossRefGoogle Scholar
  5. 5.
    Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated microRNAs impair TGF beta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13:272–286.PubMedCrossRefGoogle Scholar
  6. 6.
    Kim YK, Yu J, Han TS, et al. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 2009;37:1672–1681.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Yao Y, Suo AL, Li ZF, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009;2:963–970.PubMedGoogle Scholar
  8. 8.
    Black AR, Black JD, Azizkhan-Clifford J. Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol. 2001;188:143–160.PubMedCrossRefGoogle Scholar
  9. 9.
    Kim TH, Chiera SL, Linder KE, et al. Overexpression of transcription factor sp2 inhibits epidermal differentiation and increases susceptibility towoundand carcinogen-induced tumorigenesis. Cancer Res. 2010;70:8507–8516.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–838.PubMedCrossRefGoogle Scholar
  11. 11.
    Zhang F, Yang Z, Cao M, et al. MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer. Cancer Lett. 2014;342:121–129.Google Scholar
  12. 12.
    Wada R, Akiyama Y, Hashimoto Y, et al. miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. Int J Cancer. 2010;127:1106–1114.PubMedCrossRefGoogle Scholar
  13. 13.
    Xia Y, Chen Q, Zhong Z, et al. Down-regulation of miR-30c promotes the invasion of non-small cell lung cancer by targeting MTA1. Cell Physiol Biochem. 2013;32:476–485.PubMedCrossRefGoogle Scholar
  14. 14.
    Gopalan V, Pillai S, Ebrahimi F, et al. Regulation of microRNA-1288 in colorectal cancer : Altered expression and its clinicopathological significance. Mol Carcinog. 2013;53:E36–E44.Google Scholar
  15. 15.
    Lang Q, Ling C. MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun. 2012;426:247–252.PubMedCrossRefGoogle Scholar
  16. 16.
    Poudel S, Song J, Jin EJ, et al. Sulfuretin-induced miR-30C selectively downregulates cyclin D1 and D2 and triggers cell death in human cancer cell lines. Biochem Biophys Res Commun. 2013;431:572–578.PubMedCrossRefGoogle Scholar
  17. 17.
    Budhu A, Jia HL, Forgues M, et al. Identification of metastasis related microRNAs in hepatocellular carcinoma. Hepatology. 2008;47:897–907.PubMedCrossRefGoogle Scholar
  18. 18.
    Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–2063.PubMedCrossRefGoogle Scholar
  19. 19.
    Rossi JJ. New hope for a microRNA therapy for liver cancer. Cell. 2009;137:990–992.PubMedCrossRefGoogle Scholar
  20. 20.
    Li D, Wang Q, Liu C, et al. Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. Toxicol Sci. 2012;125:382–391.PubMedCrossRefGoogle Scholar
  21. 21.
    Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer. 2005;41:2438–2448.PubMedCrossRefGoogle Scholar
  22. 22.
    Wang L, Wei D, Huang S, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–6380.PubMedGoogle Scholar
  23. 23.
    Stoner M, Wormke M, Saville B, et al. Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor a and Sp proteins. Oncogene. 2004;23:1052–1063.PubMedCrossRefGoogle Scholar
  24. 24.
    Abdelrahim M, Smith R III, Burghardt R, et al. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. 2004;64:6740–6749.PubMedCrossRefGoogle Scholar
  25. 25.
    Phan D, Cheng CJ, Galfione M, et al. Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. Cancer Res. 2004;64:072–078.CrossRefGoogle Scholar
  26. 26.
    Kozar K, Ciemerych MA, Rebel VI, et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell. 2004;118:477–491.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Ling Yu Zhao
    • 1
  • Yu Yao
    • 2
  • Jia Han
    • 1
  • Juan Yang
    • 1
  • Xiao Fei Wang
    • 1
  • Dong Dong Tong
    • 1
  • Tu Sheng Song
    • 1
  • Chen Huang
    • 1
    Email author
  • Yuan Shao
    • 3
    Email author
  1. 1.Department of Genetics and Cell Biology, Environment and Genes Related to Diseases Key Laboratory of Education Ministry, College of MedicineXi’an Jiaotong UniversityXi’anPeople’s Republic of China
  2. 2.Department of OncologyFirst Affiliated Hospital of Medical College of Xi’an Jiaotong UniversityXi’anPeople’s Republic of China
  3. 3.Department of OtorhinolaryngologyFirst Affiliated Hospital of Medical College of Xi’an Jiaotong UniversityXi’anPeople’s Republic of China

Personalised recommendations